Adjuvant Chemotherapy with Doxorubicin-Containing Regimen for 326 Stage II Breast Cancers: 15-Year Results
| Autor: | Hervé Curé, J.-L. Achard, Fabrice Kwiatkowski, Sabine Charrier, E. Belembaogo, P. Chollet, J. P. Ferriere, M. Courtadon, M. De Latour, Jacques Dauplat |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Vincristine Heart Diseases Cyclophosphamide medicine.medical_treatment Breast Neoplasms Modified Radical Mastectomy Gastroenterology Disease-Free Survival chemistry.chemical_compound Mastectomy Modified Radical Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Doxorubicin Aged Neoplasm Staging Proportional Hazards Models Chemotherapy business.industry Carcinoma Ductal Breast Middle Aged Prognosis Survival Analysis Nitrogen mustard Surgery Carcinoma Lobular Regimen Oncology chemistry Chemotherapy Adjuvant Fluorouracil Female Menopause business medicine.drug |
| Zdroj: | American Journal of Clinical Oncology. 20:219-225 |
| ISSN: | 0277-3732 |
| Popis: | Between 1975 and 1986, 326 patients with stage II breast cancer were treated with an adjuvant combination of doxorubicin, vincristine, cyclophosphamide, and 5-fluorouracil (AVCF) following regional therapy (232 modified radical mastectomy, 94 lumpectomies, 304 irradiations). The AVCF regimen consisted of 4-week cycles of doxorubicin (30 mg/m2 day 1, modified radical mastectomy), vincristine (1 mg/m2 day 2), 5-fluorouracil 400 (mg/m2), and cyclophosphamide (300 mg/m2) days 3-6. Two hundred twenty-four patients (pts) had six cycles and 102 pts 12 cycles; 90 pts also received 30 mg daily tamoxifen for 1 year after chemotherapy. As of March 1994, the median follow-up was 130 months (range 86-221). One hundred eighteen pts developed recurrences (7 local, 19 controlateral, 92 metastatic) and 104 died. Estimated disease-free survival (DFS) was 5 years, 76 +/- 5%; 10 years, 64 +/- 5%; 15 years, 54 +/- 9%. Overall survival (OS) was 5 years, 85 +/- 4%; 10 years, 70 +/- 5%; 15 years, 58 +/- 10%. Survival was affected by the number of involved lymph nodes (258 pts were N+), menopausal status (OS at 15 years: 53% for MP+ and 65% for MP-) and Scarff-Bloom-Richardson grading, but not by hormonal receptors, number of courses, or associated hormonotherapy. Minimal cardiac toxicity was induced by doxorubicin either during or subsequent to treatment completion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|